VANFLYTA Drug Patent Profile

When do Vanflyta patents expire, and what generic alternatives are available?

Vanflyta is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-two countries.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. One supplier is listed for this compound. Additional details are available on the quizartinib dihydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vanflyta

Vanflyta will be eligible for patent challenges on July 20, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 20, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VANFLYTA

International Patents:	126
US Patents:	11
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VANFLYTA

VANFLYTA is protected by eleven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-002	Jul 20, 2023		RX	Yes	Yes
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-002	Jul 20, 2023		RX	Yes	Yes			Y
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No			Y
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No

International Patents for VANFLYTA

When does loss-of-exclusivity occur for VANFLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Hong Kong

Japan

Malaysia

Russian Federation

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VANFLYTA around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200801021	Imidazolothiazole compounds for the treatment of disease
China	101868465	Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Mexico	2010002295	FORMAS SOLIDAS QUE COMPRENDEN N-(5-TER-BUTIL-ISOXAZOL-3-IL)-N ́-{4- [7-(2-MORFOLIN-4-IL-ETOXI) IMIDAZO [2,1-B]-[1,3] BENZOTIAZOL-2-IL] FENIL} UREA, COMPOSICIONES DE LAS MISMAS, Y USOS DE LAS MISMAS. (SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2 -MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHEN YL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH.)
France	24C1013
Portugal	2205244
Brazil	PI0708823

Supplementary Protection Certificates for VANFLYTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2429524	PA2024510	Lithuania		PRODUCT NAME: KVIZARTINIBAS; REGISTRATION NO/DATE: EU/1/23/1768 20231106
2429524	CR 2024 00013	Denmark		PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107
2429524	PA2024510,C2429524	Lithuania		PRODUCT NAME: KVIZARTINIBAS; REGISTRATION NO/DATE: EU/1/23/1768 20231106
2429524	2490010-2	Sweden		PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107
2429524	CA 2024 00013	Denmark		PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107
2410987	24C1013	France		PRODUCT NAME: QUIZARTINIB; REGISTRATION NO/DATE: EU/1/23/1768 20231107

VANFLYTA (Vadadustat): Market Dynamics, Investment Scenario, and Financial Outlook

Last updated: February 3, 2026

Executive Summary

VANFLYTA (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia Therapeutics and jointly marketed with Otsuka Pharmaceutical. Approved in Japan for anemia in chronic kidney disease (CKD) patients on dialysis and non-dialysis, VANFLYTA is positioned to compete within a rapidly evolving CKD anemia market. Its market trajectory depends upon regulatory approvals, regional adoption, reimbursement policies, and competitive positioning. Forecasts indicate a growing demand driven by CKD prevalence, with a projected global market size reaching $2.5-3 billion by 2030. Investment in VANFLYTA hinges on regulatory landscapes, clinical data maturation, manufacturing capacity, and strategic partnerships.

---

What Are the Market Drivers for VANFLYTA?

Driver	Impact	Details
Rising CKD Prevalence	High	Estimated 850 million globally suffer from CKD (per WHO, 2021), fueling demand for anemia therapies.
Limitations of Erythropoiesis-Stimulating Agents (ESAs)	Significant	Safety concerns (cardiovascular risk, tumor progression) with ESAs create a need for alternative oral options.
Regulatory Approvals & Reimbursement	Critical	U.S. FDA approval anticipated post-2023; reimbursement pathways influence sales potential.
Innovation and Ease of Use	Positive	Oral administration offers convenience over injectable ESAs, favoring patient adherence and market adoption.
Competing Drugs	Market Share Dynamics	Competing drugs include roxadustat (FibroGen/Astellas), molidustat, and other HIF-PHIs.

---

How Is VANFLYTA Positioned in the Global Market?

Regional Launch Status and Market Penetration

Region	Approval Status	Market Dynamics	Key Competitors
Japan	Approved (2020)	Early mover advantage; rapid expansion	Molidustat, roxadustat (pending/approved)
United States	Not yet approved (Expect 2024/2025)	High unmet need, regulatory risk	Roxadustat (FibroGen), Medice's Molidustat
Europe	Pending EMA review	Market entry contingent on approval	Roxadustat, other HIF-PHIs
Emerging Markets	Varying approvals	Significant growth potential	Local and generic HIF-PHIs

---

What is the Financial Trajectory for VANFLYTA?

Market Size & Revenue Forecasts

Year	Estimated Global CKD-Anemia Market ($ Billions)	VANFLYTA Revenue Potential ($ Millions)	CAGR	Assumptions
2023	1.2	$50-100	-	Japan launch with initial uptake
2025	1.8	$200-300	35%	US approval, increased adoption
2027	2.4	$400-600	25%	Expanded Europe, emerging markets
2030	3.0	$700-900	20%	Maturation, expanded indications

Notes:

• Market growth driven by CKD prevalence, aging populations.
• Revenue assumes successful regulatory approval, reimbursement, and market penetration.
• Competitive pressures and clinical results influence market share.

Cost Structure and Profitability Outlook

Cost Components	Estimates	Implications
Research & Development (R&D)	~$250M (2020-2023)	Non-recurring, front-loaded investments.
Manufacturing & Supply Chain	Variable	Margins depend on economies of scale.
Sales & Marketing	~$50-100M annually post-launch	Critical for market penetration.
Regulatory & Legal	Variable	Ongoing costs with evolving regional requirements.

Profitability Timeline	Projection	Key Factors
Break-even	2026-2028	Sufficient market penetration and reimbursement.
Peak margins	2028 onwards	Revenue growth offsetting fixed costs.

---

How Do Market Dynamics Influence Investment Decisions?

Regulatory Environment

Region	Status	Impact	Risks
U.S.	Expected FDA approval post-2023	High potential value	Approval delays, clinical trial results
Europe	EMA review ongoing	Entry pathway	Regulatory constraints
Japan	Approved (2020)	Early revenue	Market saturation

Competitive Landscape

Competitor	Product	Status	Differentiation	Market Share (Est.)
FibroGen/Astellas	Roxadustat	Approved in China, early in US/EU	First-mover advantage	~50% of HIF class
Akebia/Otsuka	VANFLYTA	Approved in Japan	Oral, safety profile	15-20% in Japan, growth anticipated

Key Regulatory & Policy Trends

Trend	Effect	Notes
Reimbursement policies favor oral drugs	Accelerates adoption	High in Japan, US pending
Focus on drug safety	May influence clinical trials	Safety profiles critical

---

What Are the Investment Risks and Opportunities?

Risks

Category	Details
Regulatory Delays	Approval timelines extend or are denied.
Market Penetration	Difficulties in adopting prescribed therapies relative to established standards.
Pricing & Reimbursement	Cost containment measures may restrict sales.
Competitive Risks	Emergence of superior therapies or generic entrants.
Clinical Data	Pending or future trial results could impact positioning.

Opportunities

Category	Details
First-mover advantage in Japan	Establish early market share.
US & Europe approval	Unlock high-revenue markets.
Expansion to new indications	Anemia in non-CKD populations, other hypoxia-related conditions.
Partnerships & Licensing	Accelerate commercialization and access.
Cost optimization	Improve margins through manufacturing efficiencies.

---

Comparative Analysis with Competing Drugs

Parameter	VANFLYTA	Roxadustat	Molidustat	Vadadustat (FibroGen)
Approval Status	Approved (Japan)	Pending/Approved (various regions)	Phase 3	Phase 3/4
Administration	Oral	Oral	Oral	Oral
Clinical Data Confidence	High (approved in Japan)	Established efficacy	Ongoing	Ongoing
Regulatory Risk	Medium (pending US/EU)	High	High	High
Market Penetration	Growing in Japan	Extensive (~100 countries)	Limited	Limited

---

FAQs

Q1: What is the primary therapeutic advantage of VANFLYTA over traditional ESAs?

A1: VANFLYTA offers an oral administration route, reducing injection burden, and has a safety profile potentially better suited to certain patient populations, especially given concerns over ESA-related cardiovascular events.

Q2: How might future regulatory decisions impact VANFLYTA's market?

A2: Approval in the U.S. and Europe could significantly expand its market, boosting revenues. Conversely, delays or unfavorable outcomes could constrain growth.

Q3: What is the expected timeline for VANFLYTA's global market expansion?

A3: Japan launched in 2020; US approval is anticipated around 2024-2025; European approval follows, potentially between 2025-2027.

Q4: How does VANDALYTA compare financially to competitors?

A4: While initial R&D investments are substantial, VANFLYTA's focus on markets with favorable reimbursement policies and early approval in Japan suggest promising revenue trajectories; however, ultimate profitability depends on successful market penetration.

Q5: What are the key factors to monitor regarding VANFLYTA’s future market success?

A5: Regulatory approvals, clinical trial outcomes, reimbursement policies, competitive actions, manufacturing capacity, and regional market dynamics.

---

Key Takeaways

• Market Potential: The CKD anemia market is set to grow to ~$3 billion globally by 2030, driven by increasing CKD prevalence and unmet needs.
• Regulatory Pathway: Japan's early approval positions VANFLYTA as a regional leader; US and European approvals are pivotal for broader access.
• Competitive Landscape: The HIF-PHI class is competitive, with first-mover advantages in certain regions influencing market share.
• Investment Outlook: Opportunities are significant with high-growth potential in mature markets, but risks include regulatory delays, clinical trial results, and market adoption challenges.
• Strategic Focus: Success hinges on regulatory approvals, reimbursement negotiations, manufacturing scaling, and differentiation through safety and convenience.

---

References

[1] World Health Organization. (2021). CKD Prevalence Data.
[2] Akebia Therapeutics. (2020). VANFLYTA (vadadustat) Regulatory Filings.
[3] BloombergNEF. (2022). Pharmaceutical Market Forecasts.
[4] ClinicalTrials.gov. (Various). Ongoing and completed studies on vadadustat.
[5] Otsuka, Akebia. (2022). Market Launch Announcements.